Table 1 Characteristics of the SSc patients (n = 36)
No. with available data | SSc patients (n = 36) | |
|---|---|---|
Demographics | ||
Sex, female, no. (%) | 36 | 20 (55.6) |
Age, years, mean ± SD | 36 | 57.9 ± 13.0 |
Ethnical, no. (%) | 33 | |
White | 30 (90.9) | |
Black | 2 (6.1) | |
Asian | 1 (3.1) | |
BMI, kg/m2, mean ± SD | 36 | 25.3 ± 5.9 |
Disease characteristics | ||
Cutaneous subset, limited, no. (%) | 36 | 19 (52.8) |
Disease duration, no. (%) | 36 | |
< 2 years | 14 (38.9) | |
2–4 years | 8 (22.2) | |
> 4 years | 14 (38.9) | |
Antibody status, no. (%) | 36 | |
Anti-nuclear | 34 (94.4) | |
Anti-centromere | 12 (33.3) | |
Anti-topoisomerase I | 10 (27.8) | |
Anti-ARN polymerase III | 4 (11.1) | |
Organ involvement, no. (%) | ||
Lung, no. (%) | ||
Interstitial lung disease | 36 | 22 (61.1) |
Current %FVC, median (IQR) | 34 | 90.0 (80.0; 100.0) |
Current %DLCO, median (IQR) | 32 | 60.0 (40.0; 70.0) |
Osteoarticular | 32 | 14 (43.8) |
Muscle | 24 | 6 (25.0) |
Current mRSS, median (IQR) | 33 | 12 (4.0; 21.0) |
Gastrointestinal tract | 36 | 24 (66.7) |
Pulmonary hypertension | 36 | 8 (22.2) |
Renal crisis | 36 | 0 (0.0) |
Calcinosis | 33 | 4 (12.1) |
Telangiectasia | 35 | 22 (62.9) |
Ulcer digital | 34 | 10 (29.4) |
Heart | 36 | 6 (16.7) |
Current treatment, no. (%) | ||
Steroids | 36 | 13 (36.1) |
Immunosuppressive drugs | 36 | 13 (36.1) |